Sign up to get each new magazine issue delivered to your inbox

February 2023

In our next issue, we continue investigating major trends that are expected to make a splash in 2023, including clinical trials exploring CRISPR therapeutics, and whether biologics can still make a dent for chronic obstructive pulmonary diseases (COPD).  


We will also explore advances in precision medicine, and the research field’s willingness to adopt alternate clinical trial designs, and more.

EDITORIAL

Editor | Manasi Vaidya

Writers | Fiona Barry, Urtė Fultinavičiūtė, Akosua Mireku, William Newton, Manasi Vaidya, Adam Zamecnik

Magazine Designer | Will Ingham
Graphic Designers | Anett Arc, Noemi Balint, Martina Labaiova, Tyrrell Lowe, Ashley McPherson
Lead Designer | John Hammond 

Publisher | Susanne Hauner

Advertising

Sales Manager | Tom McCormick
+44 207 8669440

Cover image: Composite. Credit: PremiumArt, Ardea-studio and Will Ingham

Pharma Technology Focus is powered by H5mag

Read past issues of Pharma Technology Focus HERE

Copyright 2022 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | Biosimilars set the stageGo to article: In this issueGo to article: ContentsGo to article: CSafeAPSGo to article: Mimotopes Company Insight Go to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: TripletreeGo to article: CommentGo to article: Cannabinoids receptors: popular preclinical target but banned in 137 countriesGo to article: Ozempic compensating for Wegovy’s supply shortage due to high demandGo to article: Manufacturing challenges set back progress of cell therapies in oncologyGo to article: Chinese transition to innovative pharma needs more investmentGo to article: DLBCL: a rapidly evolving treatment landscape with a crowded pipelineGo to article: Bio Image Systems Inc.Go to article: In DepthGo to article: Humira biosimilars set the stage for long-awaited 2023 US launchesGo to article: Expanding ketamine’s horizons for rare neurological disordersGo to article: The “Medical Bypass”: New drugs to strike obesityGo to article: Running low on comparators: drug shortages in oncology clinical trialsGo to article: ACT EU state of play: EMA’s headway to transform clinical trialsGo to article: CMO Moves: Regulatory catalysts for drug manufacturing-DecemberGo to article: EventsGo to article: Next issue